SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Cassava Sciences and its executives face a $40 million SEC settlement over manipulated data in an Alzheimer's drug trial, misleading investors with false claims of cognitive improvement and selective data reporting.
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...
Discover how Cassava Sciences Inc. secures a patent for innovative pharmaceutical compositions using crystalline and amorphous polymorphs, enhancing therapeutic efficacy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback